ReviewNature immunology2017
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.
Review in Nature immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 289 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Advanced High-grade Serous Ovarian Cancer in Blood, Ascites, Peritoneal Biopsy
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Who cites it
289 citing papers in PubMed, 442 citations in OpenAlex.
- Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial.Journal for immunotherapy of cancer · 2023Trial
- Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.Nature medicine · 2022Trial
- Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.Signal transduction and targeted therapy · 2021Trial
- DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8Oncoimmunology · 2026Article
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
- Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response.Journal for immunotherapy of cancer · 2026Article
- TransBindpMHCI: a transformer-based model for pan-specific MHC-I peptide binding prediction.BMC bioinformatics · 2026Article
- Intratumoral Three-Cell-Type Clusters Are a Conserved Feature of Endogenous Antitumor Immunity.Cancer immunology research · 2026Article
- Non-canonical and induced neoantigens as emerging sources of cancer-specific immunotherapy targets.Frontiers in immunology · 2026Review
- Site-specific neoepitope induction by RNA editing reprograms tumor immunogenicity.Frontiers in immunology · 2026Article
- NeoTCRseek: an integrated platform for high-sensitivity identification of neoantigen-specific TCR clonotypes to track clinical T-cell dynamics.Frontiers in immunology · 2026Article
- T cell immunotherapy for solid tumors: limitations, progress, and future prospects.Frontiers in immunology · 2026Review
- Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation.Cell reports. Medicine · 2025Article
- Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Cancer vaccines as enablers of immunotherapy.Nature immunology · 2025Review
- Review
- Development of iPSC-derived T cells targeting EGFR neoantigens in non-small cell lung cancer.Molecular therapy. Methods & clinical development · 2025Article
- Multi-engineered T cell vaccine boosting TCR-T cell therapy enhances anti-tumor function and eradicates heterogeneous solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Tumor-infiltrating lymphocytes in melanoma: diagnostic and prognostic implications from biopsy to circulation.The journal of liquid biopsy · 2025Review
229 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Effective clinical cancer immunotherapies, such as administration of the cytokine IL-2, adoptive cell transfer (ACT) and the recent success of blockade of the checkpoint modulators CTLA-4 and PD-1, have been developed without clear identification of the immunogenic targets expressed by human cancers in vivo. Immunotherapy of patients with cancer through the use of ACT with autologous lymphocytes has provided an opportunity to directly investigate the antigen recognition of lymphocytes that mediate cancer regression in humans. High-throughput immunological testing of such lymphocytes in combination with improvements in deep sequencing of the autologous cancer have provided new insight into the molecular characterization and incidence of anti-tumor lymphocytes present in patients with cancer. Here we highlight evidence suggesting that T cells that target tumor neoantigens arising from cancer mutations are the main mediators of many effective cancer immunotherapies in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.